Perrigo Company PLC (PRGO)
Stock Price Chart
Key Info
| Market Cap | 6.23B |
| Revenue (ttm) | 5.07B |
| Net Income (ttm) | 240.20M |
| Shares Out | 136.48M |
| EPS (ttm) | 1.75 |
| PE Ratio | 26.07 |
| Forward PE | 10.53 |
| Dividend | $0.90 |
| Dividend Yield | 1.97% |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $45.62 |
| Previous Close | $45.48 |
| Change ($) | 0.14 |
| Change (%) | 0.31% |
| Day's Open | 45.70 |
| Day's Range | 45.27 - 45.87 |
| Day's Volume | 431,827 |
| 52-Week Range | 40.01 - 63.86 |
More Stats
| Market Cap | 6.23B |
| Enterprise Value | 8.91B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | Aug 27, 2020 |
| Shares Outstanding | 136.48M |
| Float | 136.21M |
| EPS (basic) | 1.76 |
| EPS (diluted) | 1.75 |
| FCF / Share | 4.03 |
| Dividend | $0.90 |
| Dividend Yield | 1.97% |
| Earnings Yield | 3.84% |
| FCF Yield | 8.82% |
| Payout Ratio | 49.40% |
| Shares Short | 3.40M |
| Short Ratio | 4.13 |
| Short % of Float | 2.50% |
| Beta | 1.16 |
| PE Ratio | 26.07 |
| Forward PE | 10.53 |
| P/FCF Ratio | 11.34 |
| PS Ratio | 1.23 |
| PB Ratio | 1.05 |
| Revenue | 5.07B |
| Operating Income | 310.60M |
| Net Income | 240.20M |
| Free Cash Flow | 549.10M |
| Net Cash | -2.69B |
| Net Cash / Share | -19.68 |
| Gross Margin | 34.95% |
| Operating Margin | 6.12% |
| Profit Margin | 4.70% |
| FCF Margin | 10.82% |
| ROA | 2.66% |
| ROE | 4.13% |
| ROIC | 6.40% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,837 | 4,732 | 4,946 | 5,281 | 4,227 | 3,914 | 3,540 | 3,173 | 2,755 | 2,268 |
| Revenue Growth | 2.23% | -4.34% | -6.33% | 24.92% | 8% | 10.57% | 11.55% | 15.18% | 21.46% | - |
| Gross Profit | 1,773 | 1,832 | 1,980 | 2,052 | 1,644 | 1,452 | 1,280 | 1,096 | 945 | 746 |
| Operating Income | 205 | 237 | 598 | -2,000 | 673 | 571 | 679 | 569 | 490 | 336 |
| Net Income | 146 | 131 | 120 | -4,013 | 136 | 233 | 442 | 402 | 339 | 224 |
| Shares Outstanding | 136 | 138 | 142 | 143 | 139 | 115 | 93.90 | 93.20 | 92.30 | 91.40 |
| Earnings Per Share | 1.07 | 0.95 | 0.84 | -28.01 | 0.97 | 2.01 | 4.68 | 4.27 | 3.63 | 2.41 |
| EPS Growth | 12.63% | 13.1% | - | - | -51.74% | -57.05% | 9.6% | 17.63% | 50.62% | - |
| Dividend Per Share | 0.82 | 0.76 | 0.64 | 0.58 | 0.46 | 0.39 | 0.35 | 0.31 | 0.27 | 0.24 |
| Dividend Growth | 7.89% | 18.75% | 10.34% | 26.09% | 17.95% | 11.43% | 12.9% | 13.55% | 12.81% | - |
| Operating Cash Flow | 388 | 593 | 699 | 655 | 855 | 633 | 554 | 513 | 374 | 332 |
| Capital Expenditures | -138 | -103 | -88.60 | -106 | -137 | -172 | -104 | -110 | -99.40 | -57.82 |
| Free Cash Flow | 250 | 490 | 610 | 549 | 718 | 461 | 450 | 404 | 275 | 275 |
| Cash & Equivalents | 354 | 551 | 679 | 622 | 786 | 800 | 780 | 603 | 310 | 510 |
| Total Debt | 3,369 | 3,242 | 3,341 | 5,797 | 5,400 | 3,207 | 1,974 | 1,369 | 893 | 1,344 |
| Net Cash / Debt | -3,015 | -2,691 | -2,663 | -5,175 | -4,615 | -2,407 | -1,194 | -767 | -583 | -834 |
| Assets | 11,301 | 10,983 | 11,629 | 13,870 | 19,592 | 13,853 | 5,351 | 4,024 | 3,189 | 3,109 |
| Liabilities | 5,497 | 5,315 | 5,458 | 7,913 | 8,892 | 5,159 | 3,018 | 2,171 | 1,658 | 2,015 |
| Book Value | 5,804 | 5,668 | 6,171 | 5,958 | 10,699 | 8,693 | 2,333 | 1,853 | 1,531 | 1,094 |
Company Profile
Company Details
| Full Name | Perrigo Company PLC |
| Country | Ireland |
| Employees | 11,200 |
| CEO | Murray S. Kessler |
Stock Information
| Ticker Symbol | PRGO |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: PRGO |
| IPO Date | December 16, 1991 |
Description
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid, 24HR, Good Sense, Zephrex D, ScarAway, Plackers, and Rembrandt. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands and consumer focused products through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.